Control group:Lenvatinib

3 trials

Sponsors

Beijing Youan Hospital Capital Medical University, Fujian Cancer Hospital, the First Affiliated Hospital, Sun Yat-Sen University

Conditions

Hepatocellular carcinomaHepatocellular carcinoma with large portal vein tumor thrombushepatocellular cancinoma

Early Phase 1

Efficacy and safety of HAIC combined with lamvatinib in the treatment of hepatocellular carcinoma with large portal vein tumor thrombus

RecruitingChiCTR2100045228

Beijing Youan Hospital Capital Medical UniversityHepatocellular carcinoma with large portal vein tumor thrombus

Start: 2021-05-01Updated: 2021-11-16

Phase 3

A comparative clinic study of continuous hepatic artery perfusion combined with lenvatinib and lenvatinib alone in the treatment of advanced hepatocellular cancinoma

RecruitingChiCTR2100045744

Fujian Cancer Hospitalhepatocellular cancinoma

Start: 2021-07-01Updated: 2021-12-06

Camrelizumab plus Lenvatinib versus Lenvatinib as first-line therapy for advanced primary liver cancer: a phase III, multicenter, randomized controlled clinical trial

Active, not recruitingChiCTR2100052460

the First Affiliated Hospital, Sun Yat-Sen UniversityHepatocellular carcinoma

Start: 2021-11-01Updated: 2022-10-17